What are the indications, dosing schedule, technique, toxicities, and alternatives for total body irradiation as conditioning before allogeneic hematopoietic stem‑cell transplantation?

Total Body Irradiation for Allogeneic Hematopoietic Stem Cell Transplantation

Total body irradiation remains a critical conditioning component for allogeneic HSCT in acute lymphoblastic leukemia and selected high-risk hematologic malignancies, but has been largely abandoned in many other settings due to significant toxicity concerns, with chemotherapy-based alternatives now preferred for most adult patients and those with prior radiation exposure. 1

Primary Indications for TBI-Based Conditioning

Strong Indications (Where TBI Demonstrates Superiority)

• Acute lymphoblastic leukemia (ALL) represents the strongest indication, with approximately 85% of ALL patients receiving TBI-based conditioning in allogeneic HSCT, supported by superior event-free and overall survival compared to chemotherapy-only regimens 2, 3
• Blastic plasmacytoid dendritic cell neoplasm (BPDCN) shows dramatically improved outcomes when TBI is incorporated into myeloablative conditioning, with adjusted 2-year progression-free survival of 95% for MAC+TBI versus 82% for MAC without TBI, 41% for RIC+TBI, and 60% for RIC without TBI 1
• Pediatric ALL patients >4 years of age should receive TBI-based conditioning as the gold standard, confirmed by the randomized FORUM trial demonstrating superiority over chemotherapy-only regimens 3, 4

Conditional/Limited Indications

• Acute myeloid leukemia (AML) shows divided practice patterns, with approximately 45% of patients receiving TBI-based conditioning, though no clear superiority has been established 2
• Chronic myeloid leukemia (CML) similarly demonstrates split utilization at approximately 49%, without definitive evidence favoring TBI over chemotherapy-based approaches 2
• Hodgkin lymphoma may incorporate TBI in conditioning regimens for high-risk relapsed patients who have not been previously irradiated, though many groups have abandoned this approach due to toxicity 1

Settings Where TBI Should Be Avoided

• Sickle cell disease should utilize either low-dose TBI (≤400 cGy) or chemotherapy-based conditioning, with the American Society of Hematology making no preference between approaches due to very low certainty of evidence 1
• Patients with prior radiation exposure must avoid TBI entirely due to unacceptable cumulative toxicity risk 1
• Chronic lymphocytic leukemia and low-grade NHL in the autologous setting show limited TBI utilization (approximately 10% overall), suggesting chemotherapy-based alternatives are preferred 2

Dosing Schedules and Fractionation

Myeloablative TBI Protocols

• Standard myeloablative TBI delivers 12 Gy total dose using fractionated schedules to reduce toxicity compared to historical single-fraction approaches 1, 3
• Fractionation is mandatory to diminish normal tissue toxicity while maintaining anti-leukemic and immunosuppressive effects, representing a critical shift from historical single-fraction delivery 3
• Dose rate considerations must be incorporated into treatment planning, as radiobiological trade-offs exist between leukemic cell destruction, immune suppression, and normal tissue toxicity 3

Low-Dose/Reduced-Intensity TBI

• Low-dose TBI (≤400 cGy) serves as the backbone for nonmyeloablative conditioning in sickle cell disease, developed specifically to enable transplantation in adults with organ damage who cannot tolerate myeloablative regimens 1
• Testicular shielding should be employed in males receiving low-dose TBI to preserve fertility, with evidence showing no effect on male gonadal function when shielding is used 1
• Female fertility preservation remains challenging even with low-dose TBI, as patients demonstrate SCD-related reduced ovarian function pre-transplant that worsens post-transplant, though natural pregnancies remain possible 1

Technical Delivery and Sanctuary Site Coverage

Advantages of TBI

• Sanctuary site penetration represents TBI's primary advantage, achieving adequate dose delivery to areas with poor blood supply and sites protected by blood-brain barriers where chemotherapy penetration is limited 5, 3
• Dose homogeneity to bone marrow throughout the entire skeleton ensures comprehensive disease eradication, though conventional TBI techniques suffer from dose heterogeneity in other tissues 5

Technical Limitations and Evolving Approaches

• Conventional TBI delivery uses locally developed heterogeneous treatment methods with limited ability to shield organs at risk without compromising anti-leukemic and immunosuppressive effects 3
• Total marrow irradiation (TMI) represents an evolving technique that focuses radiation dose to the entire skeleton while sparing other organs, potentially delivering equivalent or higher bone marrow doses with reduced toxicity 5
• Total marrow and lymphoid irradiation (TMLI) extends TMI concepts to include lymphoid tissues, offering potential for improved therapeutic ratio through highly conformal delivery 3

Major Toxicities and Critical Complications

Life-Threatening Early Toxicities

• Pulmonary toxicity represents a major concern, with thoracic radiation within 50 days prior to transplant or large lung volumes in the radiation field associated with high post-transplant mortality 1
• Radiation myelitis poses significant risk when radiation fields encompass the spinal cord, particularly when conditioning regimens contain busulfan that readily crosses the blood-brain barrier 1, 6
• Capillary leak syndrome risk increases with certain combinations, requiring careful patient selection and monitoring 1

Long-Term Sequelae

• Second malignancies represent a major long-term concern, with case reports of myelodysplastic syndrome and acute leukemia following both TBI-based and chemotherapy-based regimens, though attribution remains difficult 1
• Growth retardation affects pediatric patients receiving TBI, representing one of multiple late effects that must be weighed against survival benefits 5
• Neurocognitive effects occur in long-term survivors, along with endocrine dysfunction and cardiometabolic complications 4
• Infertility remains a major concern, with myeloablative TBI causing permanent gonadal dysfunction in most patients without fertility preservation measures 1

Transplant-Related Mortality

• Treatment-related mortality with myeloablative conditioning reaches 30-53%, compared to 9-18% with reduced-intensity approaches, driving the development of RIC regimens 7

Chemotherapy-Based Alternatives to TBI

Standard Chemotherapy Conditioning Regimens

• Busulfan plus cyclophosphamide represents the long-established alternative to TBI for pediatric patients, though it carries significant toxicity that limits use in adults with organ damage 1, 4
• Busulfan plus fludarabine reduces toxicity compared to busulfan/cyclophosphamide but may sacrifice efficacy, prompting addition of third agents like thiotepa, melphalan, or clofarabine 4
• Treosulfan-based conditioning achieves comparable outcomes to busulfan-based regimens in pediatric ALL without requiring therapeutic drug monitoring, offering a promising alternative 4
• BEAM protocol (BCNU, etoposide, cytarabine, melphalan) serves as standard conditioning for lymphoma patients, though it is contraindicated in patients with prior dose-limiting radiation exposure 8

Reduced-Intensity Chemotherapy Alternatives

• Fludarabine, cyclophosphamide, and alemtuzumab represents the European Society for Blood and Marrow Transplantation's recommended reduced-intensity regimen, achieving profound immunosuppression with transplant-related mortality of only 9-18% 7
• Alemtuzumab inclusion is indispensable for stable engraftment in alternative donor transplants and dramatically reduces acute and chronic GVHD, though it increases viral reactivation risk requiring aggressive surveillance 7
• Cyclophosphamide dosing in RIC regimens uses 120 mg/kg or less, compared to 200 mg/kg in myeloablative protocols 7

Optimizing Chemotherapy-Based Conditioning

• Busulfan therapeutic drug monitoring is mandatory due to wide pharmacokinetic variability and narrow therapeutic window, with first-dose selection algorithms helping achieve early accurate levels 4
• Clofarabine addition to busulfan/fludarabine shows encouraging results comparable to TBI-based regimens in ALL, deserving further evaluation 4
• Pharmacogenetic variants associated with differing busulfan exposures and toxicities may enable future personalized dosing strategies 4

Decision Algorithm for TBI vs Chemotherapy-Based Conditioning

Use TBI-Based Conditioning When:

1. Patient has ALL requiring allogeneic HSCT AND has never received prior radiation therapy 2, 3
2. Patient has BPDCN AND is receiving myeloablative conditioning for allogeneic HSCT 1
3. Pediatric ALL patient >4 years of age requiring allogeneic HSCT 3, 4
4. Patient cannot achieve NGS-MRD negativity prior to allogeneic HSCT for ALL 9

Use Chemotherapy-Based Conditioning When:

1. Patient has received prior radiation therapy to any site 1
2. Adult patient with sickle cell disease requiring allogeneic HSCT (either low-dose TBI ≤400 cGy or chemotherapy-based are acceptable) 1
3. Patient has AML or CML without specific high-risk features requiring sanctuary site coverage 2
4. Patient achieves NGS-MRD negativity prior to allogeneic HSCT for ALL 9
5. Patient has lymphoma requiring conditioning (use BEAM protocol) 8
6. Fertility preservation is critical priority in young patients, particularly females 1, 7

Critical Contraindications to TBI:

• Prior radiation therapy to any site represents an absolute contraindication 1
• Planned thoracic radiation within 50 days of transplant or large lung volumes in field 1
• Conditioning regimen includes busulfan AND radiation field would encompass spinal cord 1, 6

Common Pitfalls and How to Avoid Them

• Avoid combining TBI with busulfan-containing regimens when radiation fields include the spinal cord, as busulfan crosses the blood-brain barrier and dramatically increases radiation myelitis risk 1, 6
• Do not deliver thoracic radiation within 50 days prior to high-dose therapy, as this timing is associated with high post-transplant mortality 1
• Never use TBI in patients with prior radiation exposure, as cumulative toxicity becomes unacceptable 1
• Ensure testicular shielding in males receiving low-dose TBI to preserve fertility 1
• Implement aggressive viral surveillance post-transplant when alemtuzumab is used in conditioning, as CMV and adenovirus reactivation risk is substantially increased 7
• Recognize that single-fraction TBI is obsolete—fractionated delivery is mandatory to reduce normal tissue toxicity 3